Medartis Shareholders Overwhelmingly Approve Board Proposals, Elect Yang Xu at AGM 2026
Medartis shareholders approved all board proposals with over 90.9% support and elected Yang Xu to the board, signaling strong confidence in the company's governance and strategic direction.
Medartis Holding AG (SIX: MED) announced that its shareholders approved all substantive proposals of the Board of Directors with significant majorities exceeding 90.9% at the Annual General Meeting (AGM) held on April 23, 2026, in Basel, Switzerland. The strong shareholder endorsement underscores confidence in the company's leadership and strategic direction amid its global expansion in the medical device sector.
Shareholder participation was robust, with 10,545,669 shares represented, constituting 77.4% of the total share capital. All seven standing board members were re-elected with over 93.8% support. Yang Xu was newly elected to the Board of Directors with 99.7% endorsement and will serve on the Finance and Audit Committee. Xu's election brings fresh expertise to the board, which now comprises eight members, including Chairman Marco Gadola, Vice Chairman Dr. h.c. Thomas Straumann, and others.
The AGM granted discharge to board members for the 2025 term and approved the maximum total remuneration for both the Board of Directors and the Executive Management Board. The 2025 management report and annual financial statements were approved with 99.99% support, while the remuneration report received 91.0% in a consultative vote. The sustainability report gained 99.2% endorsement, reflecting Medartis' commitment to transparent ESG practices.
Key committee appointments were confirmed: Damien Tappy and Marco Gadola will continue on the Human Resources and Compensation Committee (HRCC). The board's composition ensures continuity in oversight of strategy, innovation, and finance. Neovius AG was re-elected as independent voting representative, and Ernst & Young AG as statutory auditors.
The strong shareholder support comes as Medartis, a leading manufacturer of medical devices for surgical fixation and joint replacement, continues to expand its global footprint. With manufacturing sites in Switzerland, the US, Brazil, and France, and products in over 60 countries, the company's governance stability is critical for executing its growth strategy.
Medartis also announced its upcoming investor and corporate calendar. An investor event will be held on June 4, 2026, in Basel on the fringes of the FESSH Hand Surgery Congress. The company will publish its first-half 2026 results on August 18, 2026, followed by an analyst and media briefing. The next AGM is scheduled for April 22, 2027, at the Basel headquarters.
For details on all resolutions, visit this link. Medartis employs approximately 1,400 individuals across 12 countries and is committed to providing innovative implants and instruments to surgeons worldwide.